The traditional approach to antibacterial discovery is to target a specific antibacterial target with a single compound. This single agent/single target approach often suffers from significant drawbacks including the rapid emergence of resistance and limited bacterial spectrum. In contrast, the development of an antibacterial agent that targets two proteins within a cell provides advantages of greater potency and reduced resistance frequency. Trius has invented a novel class of Tricyclic pyrimidoindoles that inhibit GyrB and ParE (TriBE inhibitors). Previously discovered GyrB/ParE inhibitors were limited to Gram-positive profiles. 1 Many small molecule programs targeting gyrase generated lead compounds with significant lipophilicity, and were hampered by significant protein binding, limiting their utility in vivo.2 However, our current molecules demonstrate broad spectrum antimicrobial activity against key biodefense and clinically important pathogens including B. anthracis, Y. pestis, F. tularensis and B. pseudomallei as well as MRSA, E. coli, A. baumannii, K. pneumoniae and P. aeruginosa. We have successfully demonstrated in vivo efficacy in several animal models of lung infections including MRSA, A. baumannii and B. pseudomallei. The TriBE inhibitor program has several key compounds at different stages of development. Multiple intravenous (IV)-only compounds are currently being evaluated for selection as an IND candidate. In addition, progress has been made on earlier stage TriBE compounds that have the potential for oral (PO) administration, as demonstrated by efficacy in a Streptococcus pneumoniae lung infection model. Finally, we are developing TriBE prodrugs that can be delivered IV or PO. The goal ofthe current proposal is to evaluate several TriBE inhibitors (IV-only, PO and prodrugs) to determine the antimicrobial spectrum (MIC90) against important ESKAPE and biodefense pathogens, to evaluate efficacy in animal models, and to identify the PK/PD parameters that drive efficacy. These data will be used to select the final candidates for preclinical development for both IV and PO treatment.

Public Health Relevance

The testing and selection of compounds described in this proposal will contribute to the development of this novel mechanism antibiotic class and provide an important new antibiotic efficacious against multi-drug resistant bacterial pathogens and biodefense pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109713-04
Application #
9243957
Study Section
Special Emphasis Panel (ZAI1-LR-M)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
4
Fiscal Year
2017
Total Cost
$533,920
Indirect Cost
Name
Rutgers University
Department
Type
Domestic Higher Education
DUNS #
078795851
City
Newark
State
NJ
Country
United States
Zip Code
07103
Kumar, Pradeep; Capodagli, Glenn C; Awasthi, Divya et al. (2018) Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. MBio 9:
Nukaga, Michiyoshi; Papp-Wallace, Krisztina M; Hoshino, Tyuji et al. (2018) Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam. Antimicrob Agents Chemother 62:
Becka, Scott A; Zeiser, Elise T; Marshall, Steven H et al. (2018) Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans. Diagn Microbiol Infect Dis 92:253-258
Vila-Farres, Xavier; Chu, John; Ternei, Melinda A et al. (2018) An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds. mSphere 3:
Papp-Wallace, Krisztina M; Barnes, Melissa D; Alsop, Jim et al. (2018) Relebactam Is a Potent Inhibitor of the KPC-2 ?-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 62:
Lane, Thomas; Russo, Daniel P; Zorn, Kimberley M et al. (2018) Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Mol Pharm 15:4346-4360
Papp-Wallace, Krisztina M; Nguyen, Nhu Q; Jacobs, Michael R et al. (2018) Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using ?-Lactamase Inhibitors and ?-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem 61:4067-4086
Lin, Wei; Das, Kalyan; Degen, David et al. (2018) Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). Mol Cell 70:60-71.e15
Inoyama, Daigo; Paget, Steven D; Russo, Riccardo et al. (2018) Novel Pyrimidines as Antitubercular Agents. Antimicrob Agents Chemother 62:
Becka, Scott A; Zeiser, Elise T; Barnes, Melissa D et al. (2018) Characterization of the AmpC ?-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother 62:

Showing the most recent 10 out of 23 publications